NEJM Retracts avacopan article
1 July, 2026
Last week added another significant step to the avacopan story: on 29 June 2026, the New England Journal of Medicine retracted the original 2021 ADVOCATE article on Tavneos.
What’s going on in the world of vasculitis…?
Last week added another significant step to the avacopan story: on 29 June 2026, the New England Journal of Medicine retracted the original 2021 ADVOCATE article on Tavneos.
CSL Vifor Reaffirms Its Commitment to the Vasculitis Community Amid difficult news, a partner that stays present. On the same
News | 26 June 2026 EMA Recommends Withdrawal of Tavneos (Avacopan) from the European Market The European Medicines Agency (EMA)
EMA strengthens liver monitoring requirements for Tavneos (avacopan) The safety committee of the European Medicines Agency (EMA), the PRAC, adopted
Patients Worldwide Invited to Participate International Survey on Living with Cogan’s Syndrome. Oxford University Hospitals NHS Foundation Trust is conducting
UK regulator opens a review and medical journal launches an investigation Two further developments concerning avacopan — marketed as Tavneos,